Alnylam Pharmaceuticals, Inc. (ALNY) News
Follow Alnylam Pharmaceuticals, Inc. (ALNY) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 60 public stories across 18 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
UBS Says Alnylam Fundamentals Remain Strong Despite Lower-End Guidance Expectations
UBS says Alnylam Pharmaceuticals' fundamentals remain strong despite expectations for guidance at the lower end.
EQUITY | Oct 30, 2026, 05:03 PM UTC
M
RBC Says Alnylam Q3 Update Disappoints as TTR Revenue Trends Toward Low End
EQUITY | Oct 30, 2026, 04:12 PM UTC
M
Alnylam Shares Decline 28.31% as Law Firm Investigates
The Law Offices of Howard G. Smith says it is continuing a securities fraud investigation after Alnylam Pharmaceuticals shares fell 28.31%.
EQUITY | Oct 29, 2026, 08:44 PM UTC
M
Alnylam Reports Quarterly Results Through September 30
Alnylam Pharmaceuticals reported results for the quarter ended September 30. The alert provides no financial figures.
EQUITY | Oct 29, 2026, 07:15 PM UTC
M
Alnylam Shares Fall About 26% on Demand and Pipeline Concerns
Alnylam signaled slower-than-expected demand growth for AMVUTTRA and pushed back certain trial results, while citing near-term Medicare Advantage restrictions and proposed drug reimbursement pressures.
EQUITY | Oct 29, 2026, 06:26 PM UTC
M
Alnylam Q3 Revenue Reaches $1.46 Billion; Reaffirms 2026 Guidance
Q3 revenue exceeded FactSet consensus of $1.43 billion, with adjusted earnings of $16.26 per share. Product sales rose 59% year over year to $1.15 billion; the company cited slower US demand growth than in Q2. Revenue in
EQUITY | Oct 29, 2026, 06:03 PM UTC
M
Alnylam shares fall 14.9% after pricing warning
Alnylam Pharmaceuticals shares fell 14.9% after the company warned that drug pricing adjustments could weaken demand.
EQUITY | Oct 29, 2026, 03:48 PM UTC
M
Alnylam shares plunge after warning of possible demand decline from drug-price revisions
Alnylam Pharmaceuticals shares fell after the company warned that drug-price revisions could reduce demand.
EQUITY | Oct 29, 2026, 03:48 PM UTC
M
Nasdaq Halts Trading for Volatility
Nasdaq reports a volatility trading pause at 09:35 AM.
EQUITY | Oct 29, 2026, 01:39 PM UTC
M
Alnylam shares hit over two-year low, down 16%
Alnylam Pharmaceuticals shares hit an over two-year low after Q3 results and were last down 16%.
EQUITY | Oct 29, 2026, 01:37 PM UTC
M
Alnylam shares extend losses, last down 18.5%
EQUITY | Oct 29, 2026, 01:19 PM UTC
M
Alnylam Q3 Non-GAAP Net Income and Revenue Rise; 2026 Outlook Kept
EQUITY | Oct 29, 2026, 12:49 PM UTC
M
Alnylam Reports Q3 Results, Guides FY26 Revenue Below Consensus
Alnylam reported Q3 earnings of $16.26 per share; the figure may not be comparable with the FactSet consensus of $1.
EQUITY | Oct 29, 2026, 12:44 PM UTC
M
Alnylam shares fall 6.4% premarket after Q3 results
EQUITY | Oct 29, 2026, 12:43 PM UTC
M
Alnylam Pharmaceuticals Q3 2026 Earnings Call Begins
Alnylam Pharmaceuticals' quarterly earnings call has begun.
EQUITY | Oct 29, 2026, 12:28 PM UTC
M
Alnylam Q3 Net Income Rises to $2.17 Billion
EARNINGS | Oct 29, 2026, 12:23 PM UTC
L
Alnylam Books $1.9B Third-Quarter Income Tax Benefit
EARNINGS | Oct 29, 2026, 12:13 PM UTC
M
Alnylam raises third-quarter 2026 net profit
EARNINGS | Oct 29, 2026, 12:11 PM UTC
M
Alnylam Expects 2026 Product Revenue of $4.70B-$5.10B
EARNINGS | Oct 29, 2026, 12:11 PM UTC
M
Alnylam Reports Q3 Revenue of $1.46B
Alnylam reported Q3 revenue of $1.46 billion, versus a FactSet estimate of $1.43 billion.
EQUITY | Oct 29, 2026, 12:05 PM UTC
M
Alnylam Pharmaceuticals Reports Q3 Operating Income of $345.798 Million
EARNINGS | Oct 29, 2026, 12:04 PM UTC
M
Alnylam Pharmaceuticals Reports Q3 Net Income of USD 2,167.335 Million
EARNINGS | Oct 29, 2026, 12:04 PM UTC
M
Alnylam Q3 Adjusted EPS $16.26 vs. IBES Estimate of $1.62
EARNINGS | Oct 29, 2026, 12:04 PM UTC
M
Alnylam Reports Third-Quarter 2026 Revenue of $1.292 Billion, Up 52%
Alnylam said global net product revenues were $1.292 billion, up 52% year over year. The supplied report is truncated.
EQUITY | Oct 29, 2026, 12:02 PM UTC
M
Alnylam Reports Positive Initial Phase 1b Data for Brezosiran
Alnylam reported positive initial Phase 1b results for ALN-HTT02, an investigational RNAi therapy for Huntington’s disease, demonstrating deep and durable huntingtin lowering.
EQUITY | Oct 23, 2026, 07:45 AM UTC
H
Stock Market Today: S&P 500 Slips as Micron Fails to Impress, 10-Year Yields Ease to 5.25%
The S&P 500 slipped at midday Thursday as Micron Technology Inc. (NASDAQ: MU ) fell 1.6% despite a record quarter, with the 10-year Treasury yield hovering near 5.25% and oil climbing back above $92. Micron reported fisc
LIVE | Oct 01, 2026, 04:48 PM UTC
M
US session market picture: S&P 500 +0.1%, Nasdaq 100 +0.31%; EUR/USD -0.22%, WTI -2.21%, EA leads volume
US session market picture. US index futures: S and P futures is up 0.1 percent, Nasdaq futures is up 0.31 percent, Dow futures is up 0.07 percent and Russell futures is up 0.15 percent. In currencies, the dollar index is
EQUITY | Sep 29, 2026, 01:32 PM UTC
L
Jefferies raises Jefferies Alnylam price target to $260
Jefferies raised its price target on Alnylam Pharmaceuticals to $260.00 per share from $230.00 and maintained a Hold rating, according to Benzinga/TradingView News.
EQUITY | Sep 08, 2026, 03:48 PM UTC
M
ALNY optimism on AMVUTTRA growth, reduced competition and pipeline progress
TradingView News cites strong AMVUTTRA cardiomyopathy launch-driven revenue and first-line market growth. It also points to extended tafamidis exclusivity, a failed rival trial, international expansion, and pipeline prog
EQUITY | Sep 08, 2026, 02:21 PM UTC
L
ALNY: AMVUTTRA’s first-line growth, strong data, and pipeline advances drive optimism for future expansion
AMVUTTRA’s strong commercial growth is driven by first-line adoption, robust clinical data, and broad access, with ex-U.S. expansion expected to accelerate after initial pricing adjustments. Competitive and pricing risks
EQUITY | Sep 08, 2026, 01:45 PM UTC
L
Stephens watchlist flags potential S&P Dow Jones September index changes
Stephens identified companies that could be added to, moved between, or removed from S&P Dow Jones Indices in the third-quarter rebalance after the close on Friday, September 18.
EQUITY | Sep 03, 2026, 04:05 PM UTC
L
Alnylam to webcast presentations at upcoming September investor conferences
Alnylam Pharmaceuticals said management will present company overviews at upcoming September investor conferences, with live audio webcasts available on the Investors section of its website.
EQUITY | Sep 02, 2026, 12:01 PM UTC
L
HC Wainwright maintains Alnylam price target at $455
HC Wainwright & Co. maintained its Alnylam Pharmaceuticals price target of $455.00 per share, according to Benzinga/TradingView News.
EQUITY | Sep 02, 2026, 10:28 AM UTC
H
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Tre
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
GEOPOLITICS | Aug 30, 2026, 12:23 PM UTC
L
IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY
IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY
EQUITY | Aug 28, 2026, 09:19 PM UTC
H
Alnylam cuts 2026 Amvuttra revenue guidance
Alnylam Pharmaceuticals cuts full-year 2026 revenue guidance for its Amvuttra franchise after early demand was inflated by a rush of pent-up patients.
EARNINGS | Aug 20, 2026, 04:03 PM UTC
L
BMO initiates ALNY at Outperform with $318 target
BMO assigns ALNY an Outperform rating and a $318 price target.
EQUITY | Aug 19, 2026, 11:48 AM UTC
L
BMO, Wedbush, Wolfe and RBC issue stock initiations
BMO, Wedbush, Wolfe, RBC and Cantor initiate coverage with ratings changes on AKTS, ALNY, ASND, BCAX, BMRN, CATX, PRME, AFL, AGMB, COR and MCK.
EQUITY | Aug 19, 2026, 11:09 AM UTC
H
Stocks Rise After Upgrades, Initiations
Select stocks gain after upgrades and initiations
EQUITY | Aug 03, 2026, 11:52 AM UTC
H
ALNY Upgraded to Strong Buy at Raymond James
ALNY upgraded with $420 price target
EQUITY | Aug 03, 2026, 11:48 AM UTC
H
Alnylam Selloff Creates Entry Point
Alnylam selloff creates attractive entry point
EQUITY | Aug 03, 2026, 11:13 AM UTC
H
Alnylam Maintains Outperform
Alnylam price target lowered to $350
EQUITY | Jul 31, 2026, 12:52 PM UTC
H
Alnylam PT Cut to $350 at RBC
RBC cuts Alnylam price target
EQUITY | Jul 31, 2026, 12:01 PM UTC
H
ALNY Reiterate Buy and lowering PT from $444 to $318 after Q2 results @ Stifel
ALNY Reiterate Buy and lowering PT from $444 to $318 after Q2 results @ Stifel
EARNINGS | Jul 31, 2026, 11:37 AM UTC
H
Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks
Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY ) stock plunged on Thursday after the company lowered its fiscal 2026 guidance. The company reported second-quarter adjusted earnings of $1.84 per share, beating the consensus o
EARNINGS | Jul 30, 2026, 06:37 PM UTC
H
ALNY lows -30% after results
ALNY lows -30% after results
EARNINGS | Jul 30, 2026, 06:08 PM UTC
H
Stock Market Today: Microsoft Ignites Chip Rebound as SanDisk Jumps 24%
U.S. equities clawed back Wednesday’s post-Fed losses by midday Thursday, with a blowout cloud print from Microsoft Corp. (NASDAQ: MSFT ) reviving the artificial intelligence trade and dragging beaten-down semiconductor
EARNINGS | Jul 30, 2026, 05:29 PM UTC
H
Gold Surges 3%; Bristol-Myers Squibb Earnings Top Views
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 200 points on Thursday. The Dow traded up 0.40% to 51,801.63 while the NASDAQ surged 2.08% to 24,952.56. The S&P 500 also rose,
EARNINGS | Jul 30, 2026, 04:02 PM UTC
L
ALNY -23.2%, CROX -12.3%, FICO -10.8%, H -9.1%, CVNA -9.8%, WWD -9.8%, TW -9.8%, NXLH -9.5%, META -9.6%, CHRW -10%, LHX -8.3%, FTAI -8%, MO
ALNY -23.2%, CROX -12.3%, FICO -10.8%, H -9.1%, CVNA -9.8%, WWD -9.8%, TW -9.8%, NXLH -9.5%, META -9.6%, CHRW -10%, LHX -8.3%, FTAI -8%, MO -7.3%, WDAY -8%, CRS -7.6%, OMC -6.1%, TEAM -7.4%, INTU -6.1%, HUBS -6%, HPQ -6%
EQUITY | Jul 30, 2026, 01:38 PM UTC
H
Alnylam Pharmaceuticals Posts Q2 Adjusted EPS $1.84
Alnylam beats Q2 adjusted EPS estimate
EARNINGS | Jul 30, 2026, 01:15 PM UTC
H
Alnylam trims 2026 sales forecast
Alnylam cuts 2026 product sales forecast
EARNINGS | Jul 30, 2026, 12:37 PM UTC
H
US Stocks Rise After Earnings
US stocks gain after earnings reports
EARNINGS | Jul 30, 2026, 12:26 PM UTC
H
Alnylam Pharmaceuticals Lowers FY2026 Sales Guidance from $5.300B-$5.800B to $5.275B-$5.725B vs $5.580B Est
Alnylam Pharmaceuticals (NASDAQ: ALNY ) lowers FY2026 sales outlook from $5.300 billion-$5.800 billion to $5.275 billion-$5.725 billion vs $5.580 billion estimate.
EARNINGS | Jul 30, 2026, 12:03 PM UTC
H
ALNY Alnylam Pharmaceuticals RESULTS: Q2, Q2 ADJ Net Income $251.801M, Q2 Operating Income $231.441M, Q2 ADJ Operating Income $318.066M, Q2
ALNY Alnylam Pharmaceuticals RESULTS: Q2, Q2 ADJ Net Income $251.801M, Q2 Operating Income $231.441M, Q2 ADJ Operating Income $318.066M, Q2 ADJ EPS $1.84 vs. EST $1.55, Q2 Net Income $164.494M, Q2 REV $1,290.948M vs. EST
EARNINGS | Jul 30, 2026, 12:02 PM UTC
H
earnings calendar: • earnings before the open: abev adt aep ag agco agio algm alny amcx amrx aos apd apg avy bax bc bdc bdrbf bfly bgc bi bl
earnings calendar: • earnings before the open: abev adt aep ag agco agio algm alny amcx amrx aos apd apg avy bax bc bdc bdrbf bfly bgc bi bldr bmy bud ccc cfr chkp ci cmco cnk cnx crh crox crs csw cwt dar dfin dsx dtm ee
EARNINGS | Jul 30, 2026, 11:18 AM UTC
H
Implied EPS movers for tomorrow AM: MA +/-2.8%, VLO +/-3.9%, AEP +/-4.6%, BMY +/-3.7%, ICE +/-3.4%, REGN +/-4.3%, TT +/-7.2%, EXC +/-4.3%, P
Implied EPS movers for tomorrow AM: MA +/-2.8%, VLO +/-3.9%, AEP +/-4.6%, BMY +/-3.7%, ICE +/-3.4%, REGN +/-4.3%, TT +/-7.2%, EXC +/-4.3%, PWR +/-11.7%, ALNY +/-9.9%, XEL +/-6.3%, MO +/-3.3%, SO +/-2.0%, YUM +/-6.0%, CI
EARNINGS | Jul 29, 2026, 06:05 PM UTC
H
ALNY Earnings pre-market tomorrow: qtr EPS est $1.55 (high $2.28/low $1.00), 30-day avg EPS revision -5.6% (5 analyst(s) revised up, 3 down)
ALNY Earnings pre-market tomorrow: qtr EPS est $1.55 (high $2.28/low $1.00), 30-day avg EPS revision -5.6% (5 analyst(s) revised up, 3 down), qtr revs est $1.32B; FY EPS est $7.10, FY revs est $5.58B; short interest 4.32
EARNINGS | Jul 29, 2026, 05:07 PM UTC
H
Alnylam Pharmaceuticals' Q2 Results to Determine 2026 Revenue Outlook, BofA Securities Says
() -- Alnylam Pharmaceuticals' (ALNY) Q2 financial results will be important in determining where 2026 revenue will fall within the guidance range and whether management would further refine that guidance, BofA Securitie
EARNINGS | Jul 14, 2026, 02:52 PM UTC
L
ALNY PT reduced from $460 to $410, maintains Buy @ BAML
ALNY PT reduced from $460 to $410, maintains Buy @ BAML
EQUITY | Jul 14, 2026, 12:24 PM UTC
H
Why Ultra Clean Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
Shares of Ultra Clean Holdings Inc (NASDAQ: UCTT ) rose sharply in pre-market trading after the company announced the appointment of Michael Keogh as CFO. The company appoints Michael Keogh as CFO, effective Aug. 25, suc
EARNINGS | Jul 09, 2026, 08:53 AM UTC